RxDoctor Payments Data

Charles Devine, MD

Psychiatry · Brandon, FLNPI 1881687663

Payments from drug & device makers

$131,408in general payments, 2019–2025

Across 469 payments — averaging $280.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$64K
  • AbbVie$52K
  • Otsuka America Pharmaceutical, Inc.$6K
  • Takeda Pharmaceuticals U.S.A., Inc.$5K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Neuronetics, Inc.$814
  • plus $3K from 13 others

What the payments were for

  • Speaking & faculty fees$117,18289%
  • Travel & lodging$5,3314%
  • Food & beverage$8,7757%
  • Education$1210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,408 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$191,769
Medicare patients
308
Services billed
1,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl50$78,507
NuedextaDextromethorphan Hbr/Quinidine12$20,161
TrintellixVortioxetine Hydrobromide18$15,400
AuvelityDextromethorphan Hbr/Bupropion17$15,269
FetzimaLevomilnacipran Hcl17$11,995
Quetiapine Fumarate ErQuetiapine Fumarate35$10,015
Olanzapine220$9,526
Aripiprazole173$5,126
Duloxetine Hcl225$5,029
Quetiapine Fumarate325$4,756
Ziprasidone Hcl41$3,548
Vilazodone Hcl17$2,475
Bupropion XlBupropion Hcl131$2,463
Escitalopram Oxalate208$2,246
Venlafaxine Hcl ErVenlafaxine Hcl78$2,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$51,595$90,50267 claims
Avanir Pharmaceuticals, Inc.Nuedexta$64,108$20,16112 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$4,686$15,40018 claims
Axsome Therapeutics, Inc.Auvelity$483$15,26917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →